Age is associated with reduced efficacy of vaccines and linked to higher risk of severe
COVID-19. Here we determined the impact of ageing on the efficacy of a SARS-CoV-2 …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
has raised concerns about reduced vaccine effectiveness and the increased risk of infection …

Currently approved COVID-19 vaccines prevent symptomatic infection, hospitalization, and
death from the disease. However, repeated homologous boosters, while considered a …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be expanding
the pandemic disease across the globe. Although SARS-CoV-2 vaccines were rapidly …

Background In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) was
identified as the etiological agent of severe acute respiratory syndrome, a disease …

The SARS-CoV-2 pandemic urgently calls for the development of effective preventive tools.
COVID-19 hits greatly the elder and more fragile fraction of the population boosting the …

The COVID-19 pandemic presents an unprecedented challenge to global public health.
Rapid development and deployment of safe and effective vaccines are imperative to control …

The rapidity with which vaccines against COVID-19 have been developed and tested is
unprecedented. As classically the case with randomized clinical trials, many studies …

Background Testing of vaccine candidates to prevent infection with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased …

Age is the major risk factor for mortality after SARS-CoV-2 infection and older people have
received priority consideration for COVID-19 vaccination. However, vaccine responses are …